HTFL Share Price Performance
US$25.83
-2.92 (-10.16%)
30.2% undervalued intrinsic discount
US$37.00
Fair Value
Price US$25.83
AnalystConsensusTarget US$37.00
Fair ValueUS$37.00
Share Pricen/a
Seeking Alpha • Jul 12
HeartFlow, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 3 Fair Values set on narratives written by author
HTFL Community Narratives
AN
Fair Value
·Fair Value US$37 30.2% undervalued intrinsic discount
Coronary CT Adoption And AI Platform Will Support A Stronger Long Term Outlook
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Coronary CT Adoption And AI Platform Will Support A Stronger Long Term Outlook
HeartFlow rides a shift toward heart CT scans as an earlier test for chest pain, which could feed more cases into its AI software and expand how hospitals use it across care. The upside depends on insurance coverage and doctor adoption catching up—while heavy spending and slower uptake could keep losses around longer than hoped.Read more
AN
US$37
30.2% undervalued intrinsic discount
Fair Value
Profit Margin
6.69%
Future PE
198.57x
Price in 2029
US$46.36
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
HTFL: Beat And Raise Performance Will Face Sector Pressure Ahead
Fair Value: US$37 30.2% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
HeartFlow, Inc. Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Aug 13, 2026
- -1.30
- 78.06%
- -58.42%
- 0%
About HTFL
- Founded
- 2007
- Employees
- 843
- CEO
- WebsiteView website
HeartFlow, Inc., a medical technology company, provides non-invasive solutions for diagnosing and managing coronary artery diseases the United States and worldwide. Its HeartFlow Platform uses AI and computational fluid dynamics to creates a personalized 3D model of a patient’s heart from a single coronary computed tomography angiography, a specialized type of scan that provides detailed images of the heart’s arteries. The company provides Heartflow RoadMap Analysis that offers an intuitive anatomic visualization of the coronary arteries; Heartflow FFRCT Analysis, which calculates blood flow and pinpoints clinically; and Heartflow Plaque Analysis that provides a comprehensive assessment of coronary plaque, enabling optimized medical treatment strategies. Its platform provides insights on blood flow, stenosis, and plaque volume and composition by overcoming the limitations of traditional non-invasive imaging tests. HeartFlow, Inc. was formerly known as Cardiovascular Simulation, Inc. and changed its name to HeartFlow, Inc. in May 2009. The company was incorporated in 2007 and is headquartered in San Francisco, California.
